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SUMMARY
MicroRNAs (miRNAs) are differentially expressed in the brain under pathologic condi-
tions andmay therefore represent both therapeutic targets and diagnostic or prognos-
tic biomarkers for neurologic diseases, including epilepsy. In fact, miRNA expression
profiles have been investigated in the hippocampi of patients with epilepsy in compar-
ison with control, nonepileptic cases. Unfortunately, the interpretation of these data is
difficult because surgically resected epileptic tissue is generally compared with control
tissue obtained from autopsies. To challenge the validity of this approach, we per-
formed an miRNA microarray on the laser microdissected granule cell layer of the
human hippocampus obtained from surgical samples of patients with epilepsy, autop-
tic nonepileptic controls, and patients with autoptic epilepsy, using the latter as inter-
nal control. Unfortunately, it is extremely difficult to collect autopsy material from
documented epilepsy individuals who died of non–epilepsy-related causes—we found
only two such cases. However, hierarchical clustering of all samples showed that those
obtained from autopsies of patients with epilepsy segregated with the other autoptic
samples (controls) and not with the bioptic tissues from the surgery patients, suggest-
ing that the origin of the tissue (surgery or autopsy)may be prevalent over the underly-
ing pathology (epilepsy or not epilepsy). Even taking into account the limitations due
to the small number of cases, this observation arises concerns on the use of autopsy tis-
sue as control for this kind of studies.
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MicroRNAs (miRNAs), are small, endogenous, noncod-
ing RNAs that regulate gene expression at the posttranscrip-
tional level by inhibiting mRNA translation. About 70% of
the known miRNAs are expressed in the brain, and many
are specific to neurons.1 It has been hypothesized that miR-
NAs might actively participate in the pathogenesis of cen-
tral nervous system (CNS) diseases; their expression levels
have been investigated in many neurologic disorders,
including Alzheimer disease, Parkinson disease,2,3 and tem-
poral lobe epilepsy (TLE).4–8
miRNAs may represent novel therapeutic targets for
these diseases. For example, the silencing of miR-134 has
been demonstrated to exert prolonged seizure-suppressant
and neuroprotective actions in a murine model of epilepsy.9
Moreover, miRNAs may serve as disease biomarkers.10,11
With reference to epilepsy, studies in rodents found a corre-
lation between specific miRNA expression patterns and the
phase of the disease.4,6,7 If confirmed in humans, these
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patterns may help to predict patients who will develop epi-
lepsy after a potentially epileptogenic insult. Moreover,
analysis of miRNA expression in surgical samples may help
in the prognostic evaluation of postsurgical epilepsy.5
miRNA expression profiles have been also investigated
in the hippocampus of patients with TLE in comparison
with control, nonepileptic cases.12 These studies12 raise the
following concerns: (1) the use of heterogeneous brain areas
like the hippocampus may influence the miRNA expression
levels compared to healthy cases, because the cellular com-
position of an epileptic brain is dramatically changed com-
pared with the normal tissue (e.g., neuronal loss,
astrocytosis, and microgliosis); (2) the interpretation of
these data is difficult also because the control tissue used to
investigate miRNA expression levels was from autopsies,
whereas the epileptic tissue was from surgical specimens,
and it is questionable if autopsy samples are valid controls
for surgical epilepsy samples.
Therefore, the aim of this study was to challenge the
validity of this approach. First, we strongly attenuated the
confound of cell heterogeneity by performing an miRNA
microarray on the laser microdissected granule cell layer of
the hippocampus, a nearly homogeneous preparation. Sec-
ond, we compared bioptic (surgical) samples of TLE
patients, autoptic (nonepileptic) controls, and autoptic
epileptic patients, using these latter as an “internal control”
for the hierarchical cluster analysis. The assumption was
that, if autopsy controls were valid, the autopsy epilepsy
group would segregate with the surgery epilepsy group. If
instead the controls were not valid, that is, if the postmortem
condition was prevalent over the disease condition, the
autopsy epilepsy group would segregate with the autopsy
control group. Unfortunately, it is difficult to obtain autopsy
material from documented epilepsy individuals who died
because of non–epilepsy-related causes, and we managed to
find only two such cases.
Materials and Methods
Patients and controls
The present study was approved by the Ethics Committee
of Bologna (Comitato Etico Indipendente dell’Azienda
USL della Citta di Bologna). Surgical hippocampal samples
from 12 drug-resistant TLE patients (3 male and 9 female)
were collected at the Epilepsy Surgery Center of the IRCCS
Institute of Neurological Sciences of Bologna (Table 1).
Epileptologic evaluation, wakefulness/sleep electroen-
cephalography (EEG), and continuous long-term video-
EEG monitoring for seizure recording were performed on
all epileptic patients before surgery. Ictal clinical and EEG
semiology and electroclinical correlations were used to
identify the epileptogenic area. Brain magnetic resonance
imaging (MRI) and computed tomography (CT) scan (when
necessary) were also used for proper identification of
the epileptogenic focus. The main surgical specimens
(hippocampus and/or temporal pole) were removed “en
bloc” and spatially oriented to allow a proper histopatho-
logic examination. All the methods were carried out in
accordance with the approved guidelines, and samples were
handled in compliance with the Helsinki declaration (http://
www.wma.net/en/30publications/10policies/b3/).
Autoptic hippocampal tissue was from two epileptic
patients (both female) who died of lung pathologies and 10
patients (three male and seven female) without history of
epilepsy or seizures (Table 1). All these samples were from
the tissue bank of the Bellaria Hospital in Bologna and our
institutional review board or ethics committee waived the
need for informed consent.
Histology andmicrodissection
After collection, tissues obtained from both surgeries
and autopsies were immediately immersed in formalin
for 48–72 h, and then paraffin embedded. Ten-micron–
thick sections were cut and mounted on slides for laser
microdissection (LMD). Samples were de-waxed, washed
in ethanol, and stained with hematoxylin. Hippocampal
samples from autoptic cases did not display signs of
hypoxia, for example, red degeneration features such as
pronounced cytoplasmic eosinophilia, collapse of cyto-
plasm with accentuated (artifactual) pericellular spaces,
or pyknotic nuclei with indistinct nucleoli. In addition,
the cerebellar granular layer did not present autolytic
swelling or status spongiosus.13
Laser microdissection was then performed essentially as
described previously.5 Briefly, slides were positioned in a
stencil laser (SL) microcut/microtest dissector (Nikon,
Tokyo, Japan). The intensity, aperture, and cutting velocity
were calibrated to obtain the sharpest cut, and the pulsed
ultraviolet (UV) laser beam was directed along the borders
of the dentate gyrus granule cell layer (GCL). To obtain an
adequate amount of tissue for RNA purification, the
microdissected GCL from at least three to four slices per
patient was pooled together. Total RNA was extracted using
an RNA purification kit (RecoverAll Total Nucleic Acid
Isolation kit; Life Technologies, CA, U.S.A.).
The concentration and the quality of the RNA were
investigated using a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Waltham, MA, U.S.A.) and an Agi-
lent 2100 Bioanalyzer. Formalin-fixed, paraffin-
embedded, laser-microdissected samples had an RNA
Integrity Number (RIN) <5 (in a scale 1–10), as expected
based on previous reports.14 This would prevent accurate
analysis of mRNAs, but not of miRNA.14 Moreover, to
increase accuracy, we verified that samples had a pick
containing miRNAs (20–25 nucleotides) in the electro-
pherograms obtained by the Bioanalyzer.
Hierarchical clustering
One hundred nanograms of total RNA per sample was
employed for microarray analysis (Human micro-RNA
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Microarray V3, #G4470C, Agilent Technologies, Santa
Clara, CA, U.S.A.). The chip allowed simultaneous analysis
of 1,200 human miRNAs obtained from the Sanger miR-
BASE database (Release 10.1). RNA labeling and
hybridization were performed according to the manufac-
turer’s indications. Row data were obtained using an Agi-
lent scanner and the Feature Extraction 10.5 software
(Agilent Technologies).
The GeneSpring GX 12 software (Agilent Technologies)
was employed to analyze microarray results. All negative
values were transformed at 1.0, followed by Quantile nor-
malization and log2 transformation. Differentially
expressed miRNAs were identified by comparing autoptic
controls with autoptic and bioptic epileptic samples, apply-
ing a twofold-change filter, the Mann-Whitney test, and
Benjamini-Hochberg correction (adjusted p < 0.05). Man-
hattan correlation was used for cluster analysis.
Results
Subjects
Surgical specimens from 12 patients with TLE indicated
in numbers in Table 1 were laser-microdissected and
employed for microarray analysis. Neuropathologic exami-
nation evidenced that all these patients had type 1 hip-
pocampal sclerosis.15 This group was composed of three
men and nine women, with mean age at surgery of 39 (31–
60), mean years after epilepsy diagnosis of 24 (7–38), and
approximately 10 seizures per month before surgery (2 to
>30). The two autoptic TLE specimens (Table 1, cases 13
and 14) also had type 1 hippocampal sclerosis. They were
from two female patients who died for lung diseases (pul-
monary edema, pneumonia). Their mean age at death was
58 (range 46–70), mean years after epilepsy diagnosis was
26 (4–48), and they had 4–30 seizures/month.
Figure 1.
Cluster analysis of miRNAs differentially expressed in the granule cell layer (GCL) in TLE patients (including two autoptic epileptic cases)
and in the control group. Each column represents an individual case and each row represents one miRNA. Colors represent the miRNA
expression level in each sample, referred to miRNA average expression: higher-red, lower-green. Differentially expressed miRNAs were
identified applying a twofold-change filter, the Mann-Whitney test, and Benjamini-Hochberg correction (adjusted p < 0.05).
Epilepsia Open ILAE
Epilepsia Open, 2(1):90–95, 2017
doi: 10.1002/epi4.12023
93
Microarray: Autoptic Versus Bioptic Tissues
Control specimens were from 10 nonepileptic individuals
listed in Table 1 (cases 15–24). This group was composed of
three men and seven women with mean age at death of 46
(34–57), who died of lung or heart diseases (pulmonary
edema, pneumonia, pulmonary thromboembolism, or
myocardial infarction) except for cases 15 and 20, who died
of cerebral infarction.
Microarray
We investigated miRNA expression in the laser-micro-
dissected granule cell layer (GCL) from the three groups:
surgical specimens of epileptic patients, autoptic samples
of cases without history of epilepsy, and autoptic samples
from TLE patients. After comparing epileptic (both
autoptic and bioptic) and control samples, we detected
significant changes in the expression levels of 106 miR-
NAs. Hierarchical clustering of all samples showed two
main clusters: all surgical epilepsy samples segregated
together in one cluster, and all autopic control cases in
the other, with the exception of two cases (nos.18 and
23) that segregated at the margin of the surgery group,
adjacent to the other autopsy cases. One surgery case (no.
10) displayed a unique profile in that, even if belonging
to the larger surgery cluster, segregated independently. In
summary, with few minor exceptions, we obtained a very
good separation between epilepsy surgery and control
autopsy cases. However, contrary to the expectation, the
two samples obtained from autopsies of TLE patients
segregated with the control group of only autoptic sam-
ples (Fig. 1).
An unsupervised principal component analysis (PCA)
plot of the data is shown in Figure 2. The analysis was per-
formed using the expression of all human miRNAs, without
any feature selection. Therefore, samples are grouped
according to their global miRNA expression profile. A clear
separation between autoptic and surgery samples can be
observed.
Discussion
Previous studies have explored differences between
miRNA expression patterns in surgical epileptic tissue com-
pared with autoptic control tissue.12 However, the possible
bias generated by the utilization of postmortem tissue was
not evaluated in depth. This study aimed at addressing this
specific issue, by introducing in the comparison a third
group, that is, autopsy specimens from individuals with epi-
lepsy. We acknowledge that a limitation of the present study
is the very limited number of cases in this group (two only).
Unfortunately, it is difficult to obtain autopsy tissue from
patients with a documented history of epilepsy, who died of
non–epilepsy-related causes. Even if it would have been
desirable to have a larger cohort of such cases, and even tak-
ing into account the considerations described in the Results
section, the segregation of these two cases with the other
autopsy, nonepileptic ones (and not with the surgical epilep-
tic, as expected) is very clear. A different pathology beyond
the source of tissue may affect miRNA signatures, because
like most autoptic control cases, two epileptic autoptic cases
died from lung diseases. In any event, this unexpected find-
ing seems to depend on postmortem modifications and not
on sample processing, because all samples (either autoptic
or bioptic) were processed in the same manner. Specifically,
we were careful that the following parameters were identi-
cal in all samples: (1) the time between tissue resection and
formalin fixation, (2) the laser microdissection procedure,
and (3) the RNA quality for miRNA detection. Although
these may not completely exclude a contribution of minor
differences in tissue processing, it seems fair to say that the
observation poses serious concerns on the use of autopsy
controls for this kind of study.
A possible approach that may be proposed to maintain
the use of control autopsy cases in this kind of study,
thereby integrating the limited number of epilepsy
autopsy cases with the much more readily available sur-
gical ones, may be to first run cluster analysis of
microarray data to compare autoptic epileptic with autop-
tic controls, and to then perform a further hierarchical
clustering on all samples (including surgical samples)
based on those miRNAs identified as differentially
expressed in the first step. We explored this possibility
with our samples, and observed significant changes in
the expression levels of 36 miRNAs between autoptic
epileptic and autoptic controls. When cluster analysis has
been run including all groups, the two autoptic epileptic
Figure 2.
Principal component analysis (PCA) plot. Scatter plot showing the
samples coordinates on the three main principal components.
Autopsy controls are represented as red squares; autopsy epilepsy
are green circles, and surgery epilepsy cases are blue triangles.
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cases segregated with the other epileptic and not with the
other autopsies (data not shown). Although this experi-
ment must be viewed as preliminary, being based on the
only two autoptic epilepsy cases, it appears to be a more
accurate approach than the surgery–epilepsy versus
autopsy–control approach. Nonetheless, further analysis
with increased cohorts of autoptic TLE cases will be
needed to unequivocally identify TLE-dependent miRNA
expression changes.
In conclusion, microarray platforms can provide impor-
tant insights in the search for novel biomarkers or therapeu-
tic targets, but limitations in the experimental approach
must be carefully considered. Even if based on a number of
cases too limited to provide conclusive evidence, the present
results indicate that the postmortem modifications may have
greater impact than the disease background on the data gen-
erated, with a potentially serious hindrance in their interpre-
tation.
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